DNMT3A and acute myeloid leukemia: Mutations in DNMT3A have been reported in AML and MDS patients, with a prevalence of 20–60% (hot spot mutation R882H) and 10% percent of patients, respectively, and are associated with an adverse prognosis (see Table 1).